GRDN Stock Analysis: Guardian Pharmacy Services | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 2.659m USD | 12M Return: 96.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 19.0M
Qual. Beats: 0
Rev. Trend: 99.7%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Seasonality 1.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Guardian Pharmacy Services (NYSE: GRDN) is a US pharmacy services company that provides technology-enabled clinical, dispensing, and administrative support to residents of long-term care facilities (LTCFs), with a focus on lower-acuity settings such as assisted living communities, behavioral health facilities, and group homes. Its proprietary platform, branded Guardian Compass, offers data-driven tools-including dashboards, the GuardianShield programs, an Order Entry QA Analyzer for prescription error detection, and a Medication Spend Analyzer-to help its local pharmacy partners and facility clients manage operations and drug costs. Headquartered in Atlanta, Georgia, and founded in 2003, the company operates within the GICS Consumer Staples / Drug Retail segment and completed its IPO in late September 2024. As a specialty LTC pharmacy operator, Guardian benefits from the fragmented nature of institutional pharmacy services and rising demand tied to the aging US population and the growing preference for non-institutional long-term care settings.
- Acquisition strategy expands pharmacy footprint across assisted living markets
- Aging US population drives long-term care facility resident growth
- Drug reimbursement rate changes pressure pharmacy gross margins
| Net Income: 53.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA 1.91 > 1.0 |
| NWC/Revenue: 5.13% < 20% (prev 1.62%; Δ 3.51% < -1%) |
| CFO/TA 0.21 > 3% & CFO 88.8m > Net Income 53.1m |
| Net Debt (-28.0m) to EBITDA (102.3m): -0.27 < 3 |
| Current Ratio: 1.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (63.7m) vs 12m ago 1.24% < -2% |
| Gross Margin: 20.93% > 18% (prev 19.78%; Δ 1.15% > 0.5%) |
| Asset Turnover: 382.7% > 50% (prev 383.9%; Δ -1.25% > 0%) |
| Interest Coverage Ratio: 122.1 > 6 (EBIT TTM 79.3m / Interest Expense TTM 649k) |
| A: 0.17 (Total Current Assets 235.2m - Total Current Liabilities 160.5m) / Total Assets 426.9m |
| B: 0.19 (Retained Earnings 79.6m / Total Assets 426.9m) |
| C: 0.21 (EBIT TTM 79.3m / Avg Total Assets 380.5m) |
| D: 1.14 (Book Value of Equity 220.9m / Total Liabilities 194.5m) |
| Altman-Z'' = 4.35 = AA |
| DSRI: 1.01 (Receivables 111.7m/97.4m, Revenue 1.46b/1.28b) |
| GMI: 0.95 (GM 19.78% / 20.93%) |
| AQI: 0.89 (AQ_t 0.24 / AQ_t-1 0.27) |
| SGI: 1.14 (Revenue 1.46b / 1.28b) |
| TATA: -0.08 (NI 53.1m - CFO 88.8m) / TA 426.9m) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 40.96 with a total of 220,511 shares traded. Over the past week, the price has changed by -2.48%, over one month by -2.41%, over three months by +4.62% and over the past year by +96.55%.
Current recommended Stop Loss: 36.70 (which is 10.4% or 2.2 ATR below the current price).
Guardian Pharmacy Services has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy GRDN.
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 47 | 14.7% |
P/E Trailing = 50.0
P/E Forward = 34.2466
P/S = 1.8266
P/B = 12.077
Revenue TTM = 1.46b USD
EBIT TTM = 79.3m USD
EBITDA TTM = 102.3m USD
Long Term Debt = 29.7m USD (estimated: total debt 36.9m - short term 7.22m)
Short Term Debt = 7.22m USD (from shortTermDebt, last quarter)
Debt = 36.9m USD (from shortLongTermDebtTotal, last quarter) (leases 36.9m already included)
Net Debt = -28.0m USD (calculated: Debt 36.9m - CCE 64.9m)
Enterprise Value = 2.63b USD (2.66b + Debt 36.9m - CCE 64.9m)
Interest Coverage Ratio = 122.1 (Ebit TTM 79.3m / Interest Expense TTM 649k)
EV/FCF = 37.59x (Enterprise Value 2.63b / FCF TTM 70.0m)
FCF Yield = 2.66% (FCF TTM 70.0m / Enterprise Value 2.63b)
FCF Margin = 4.81% (FCF TTM 70.0m / Revenue TTM 1.46b)
Net Margin = 3.64% (Net Income TTM 53.1m / Revenue TTM 1.46b)
Gross Margin = 20.93% ((Revenue TTM 1.46b - Cost of Revenue TTM 1.15b) / Revenue TTM)
Gross Margin QoQ = 22.67% (prev 21.50%)
Tobins Q-Ratio = 6.16 (Enterprise Value 2.63b / Total Assets 426.9m)
Interest Expense / Debt = 1.76% (Interest Expense 649k / Debt 36.9m)
Taxrate = 32.29% (25.4m / 78.6m)
NOPAT = 53.7m (EBIT 79.3m * (1 - 32.29%))
Current Ratio = 1.46 (Total Current Assets 235.2m / Total Current Liabilities 160.5m)
Debt / Equity = 0.17 (Debt 36.9m / totalStockholderEquity, last quarter 220.9m)
Debt / EBITDA = -0.27 (Net Debt -28.0m / EBITDA 102.3m)
Debt / FCF = -0.40 (Net Debt -28.0m / FCF TTM 70.0m)
Total Stockholder Equity = 195.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.95% (Net Income 53.1m / Total Assets 426.9m)
RoE = 27.21% (Net Income TTM 53.1m / Total Stockholder Equity 195.0m)
RoCE = 35.28% (EBIT 79.3m / Capital Employed (Equity 195.0m + L.T.Debt 29.7m))
RoIC = 25.71% (NOPAT 53.7m / Invested Capital 208.7m)
WACC = 7.57% (E(2.66b)/V(2.70b) * Re(7.66%) + D(36.9m)/V(2.70b) * Rd(1.76%) * (1-Tc(0.32)))
Discount Rate = 7.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.45 | Cagr: 2.05%
[DCF] Terminal Value 77.97% ; FCFF base≈61.4m ; Y1≈70.3m ; Y5≈103.5m
[DCF] Fair Price = 31.85 (EV 1.56b - Net Debt -28.0m = Equity 1.59b / Shares 49.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.55 | # QB: 0
Revenue Correlation: 99.72 | Revenue CAGR: 16.99% | SUE: 1.05 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.26 | Chg30d=+0.00% | Revisions=+0% | Analysts=6
EPS next Quarter (2026-09-30): EPS=0.30 | Chg30d=+0.00% | Revisions=-29% | Analysts=6
EPS current Year (2026-12-31): EPS=1.26 | Chg30d=+0.00% | Revisions=+50% | GrowthEPS=+17.8% | GrowthRev=-2.3%
EPS next Year (2027-12-31): EPS=1.36 | Chg30d=+0.00% | Revisions=+29% | GrowthEPS=+7.8% | GrowthRev=+7.6%
[Analyst] Revisions Ratio: +17% (up=9, down=6)